Condition: Sickle Cell Disease · Sponsor: Sanofi
The purpose of this study is to measure whether PCV21 vaccine (investigational pneumococcal vaccine) is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) compared with 20vPCV (licensed pneumococcal vaccine) when given as a single dose to children aged 2 to 17 years with sickle cell disease who had received or not a previous vaccination with pneumococcal conjugate or pneumococcal polysaccharide vaccine.
This description comes directly from the study's public registry record.
Trial Transparency email recommended (Toll free number for US & Canada) · 800-633-1610 · contact-us@sanofi.com
Always discuss trial participation with your own doctor first.
| Site # 8400006 | Atlanta, Georgia, United States | Recruiting |
| Site # 8400002 | Atlanta, Georgia, United States | Recruiting |
| Site # 8400003 | Omaha, Nebraska, United States | Recruiting |
| Site # 8400001 | New Brunswick, New Jersey, United States | Recruiting |
| Site # 8400004 | Houston, Texas, United States | Recruiting |
| Site # 2140001 | Santo Domingo, Dominican Republic | Recruiting |
| Site # 2140003 | Santo Domingo, Dominican Republic | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07247188